Proton-Pump Inhibitor Therapy in Patients with Gastro-Oesophageal Reflux Disease
- 1 January 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 67 (11), 1521-1530
- https://doi.org/10.2165/00003495-200767110-00001
Abstract
Proton-pump inhibitor (PPI) failure in gastro-oesophageal reflux disease (GORD) patients has become the main reason for referral of these patients to gastroenterology specialists. It is estimated that 30% of GORD patients requiring a PPI once daily will experience treatment failure. Patients with non-erosive reflux disease are the most common GORD-related group in which once-daily PPI therapy fails. Various mechanisms have been suggested to underlie PPI failure in GORD patients. The most pertinent include weakly acidic reflux, duodenogastro-oesophageal reflux, visceral hyperalgesia, delayed gastric emptying, psychological co-morbidity and concomitant functional bowel disorders, as well as others. Because of the importance of PPI failure as a target for future drug development, further understanding of the most relevant underlying mechanisms is needed.Keywords
This publication has 52 references indexed in Scilit:
- Functional Heartburn Patients Demonstrate Traits of Functional Bowel Disorder but Lack a Uniform Increase of Chemoreceptor Sensitivity to AcidThe American Journal of Gastroenterology, 2006
- Clinical and Endoscopic Features of Eosinophilic Esophagitis in AdultsGastrointestinal Endoscopy, 2003
- Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIsThe American Journal of Gastroenterology, 2003
- Nocturnal Acid Breakthrough: Clinical Significance and Correlation With Esophageal Acid ExposureThe American Journal of Gastroenterology, 2003
- Non‐erosive reflux disease (NERD) — acid reflux and symptom patternsAlimentary Pharmacology & Therapeutics, 2003
- Meta‐analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitisAlimentary Pharmacology & Therapeutics, 2001
- Is Helicobacter pylori status relevant in the management of GORD?Alimentary Pharmacology & Therapeutics, 2000
- Nocturnal Recovery of Gastric Acid Secretion With Twice-Daily Dosing of Proton Pump InhibitorsAmerican Journal Of Gastroenterology, 1998
- Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretionAlimentary Pharmacology & Therapeutics, 1997
- Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazoleGastrointestinal Endoscopy, 1996